Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 10 citing articles:

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Immunotherapy for early-stage non-small cell lung cancer: A practical guide of current controversies
William J. Phillips, Ashley Jackson, Biniam Kidane, et al.
Clinical Lung Cancer (2025)
Open Access
Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues
Pengliang Xu, Huanming Yu, Hongqiang Bian, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 110-110
Open Access
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives
Lucrezia Barcellini, Simone Nardin, G. Sacco, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 652-652
Open Access
Real-world comparison of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer: a retrospective cohort study of treatment outcomes
Yan Hu, Siying Ren, Juan Feng, et al.
Translational Lung Cancer Research (2025) Vol. 14, Iss. 2, pp. 467-479
Open Access
Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review
Xiaolin Zhao, Xiaoyu Wang, Surui Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Efficacy and Safety of Perioperative Immunotherapy for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Zhijuan Du, Siyuan Chen, Yuhui Qin, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 184-184
Open Access
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
Zedao Liu, Zhenlin Yang, Junqi Wu, et al.
Cell (2025)
Open Access
Clinical practice guidelines for perioperative multimodality treatment of non-small cell lung cancer
Wenjie Jiao, Liang Zhao, Jiandong Mei, et al.
Chinese Medical Journal (2025)
Open Access
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach
Ahsan Rizwan, Hugh Giovinazzo, Yu Tian, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 5
Open Access
New territories: perioperative chemoimmunotherapy in early-stage NSCLC
Yusuke Okuma
The Lancet Respiratory Medicine (2024)
Closed Access
Page 1

Scroll to top